


SUPPLEMENTAL MATERIALS AND METHODS

Synthesis of compound **YC-36**:




To a solution of compound **A**¹ (1.5 mg, 2.10 μ mol) in dimethylformamide (1 mL) was added triethylamine (0.005 mL, 35.9 μ mol), followed by fluorescein isothiocyanate isomer 1 (1 mg, 2.57 μ mol). After 2 hour at room temperature, the reaction mixture was purified by high performance liquid chromatography (column, Econosphere C18 5 μ , 150 \times 4.6 mm; retention time, 15 min; mobile phase, H₂O/CH₃CN/TFA = 75/25/0.1; flow rate, 1 mL/min) to afford 1.5 mg (72%) of compound **YC-36**. ESI-Mass calcd for C₄₇H₅₇N₆O₁₆S [M+H]⁺ 993.4, found 992.8.

Fluorescence-Activated Cell Sorting:



PC3 PIP and PC3 flu cells were prepared in RPMI supplemented with 1% FBS at 1 million cells per mL density. Cells were stained with 100nM YC-36 for 1 h at room temperature and washed twice with the same media. Cells were analyzed using the FACSCalibur (BD Biosciences) and FlowJo software (FLOWJO, LLC).

SPECT/CT Imaging (single photon emission computed tomography):


At 24 h post injection, the mice were anesthetized with isoflurane and maintained under 1% isoflurane in oxygen. The mice were positioned on the X-SPECT (Gamma Medica) gantry and scanned using two low energy, high-resolution pinhole collimators. All gamma images were reconstructed using LumaGEMsoftware (GammaMedica). Immediately following SPECT acquisition, the mice were then scanned by CT (X-SPECT) over a 4.6 cm field-of-view using a 600 μ A, 50 kV beam. The SPECT and CT data were then coregistered using the supplier's software (Gamma Medica) and displayed as maximum intensity projection image.



Supplemental Figure 1. Fluorescence-activated cell sorting of live cells of PSMA+ PC3 PIP (A) and PSMA- PC3 flu (B) after staining with 100nM of YC-36. Black line indicates non-stained cells, and red line indicates cells stained with YC-36.

A**B**

Supplemental Figure 2. Images of γ H2AX staining (green) in PSMA+ PC3 PIP (A) and PSMA- PC3 flu (B) cells after treatment for 18 hours with 10 μ Ci/ml 125 I-DCIBzL. Hoechst dye (blue) stains all DNA. Scale bars indicate 50 μ m. Quantification of γ H2AX foci per cell is shown in Figure 3B.



Supplemental Figure 3. Tumor growth delay in nude mice bearing PSMA+ PC3 PIP or PSMA- PC3 flu flank xenografts after treatment with 3 mCi (111 MBq) ^{125}I -DCIBzL or equal amount of control compounds ($n = 5$ mice per group; $p = 0.002$ by log rank test). This plot shows the normalized tumor size of individual animals, and the corresponding Kaplan-Meier plot is shown in Figure 5A. Please note that one animal treated with ^{125}I -DCIBzL died at 45 days after treatment due to unrelated infection with no prior weight loss or evidence of metastatic spread.

REFERENCES

1. Chen, Y.; Dhara, S.; Banerjee, S. R.; Byun, Y.; Pullambhatla, M.; Mease, R. C.; Pomper, M. G., A low molecular weight PSMA-based fluorescent imaging agent for cancer. *Biochem Biophys Res Commun* **2009**, *390* (3), 624-9.